Grahame HARDIE, PhD, FRS, FRSE, FMedSci

University of Dundee, DUNDEE, UK

Grahame Hardie was born in Liverpool in 1950, graduated in Biochemistry at Cambridge University (UK) in 1971, and has a PhD in Biological Sciences from Heriot-Watt University (Edinburgh, UK) in 1974.
Following Research posts in Portsmouth and Dundee, he was appointed as a Lecturer in Biochemistry at the University of Dundee in 1971, and was promoted to Senior lecturer in 1987, Reader in 1990 and Professor in 1994.
In recognition of his research achievements, he was elected a Fellow of the Royal Society of Edinburgh in 1998, of the UK Academy of Medical Sciences in 2002, and of the Royal Society in 2007. In 2008 he was awarded the Rolf Luft prize for Endocrinology and Metabolism by the Karolinska Institute, Sweden, and in 2010 received the Novartis Medal of the UK Biochemical Society.
He has published nearly 350 peer-reviewed scientific articles and has given around 200 invited lectures at scientific meetings in over 30 countries.  He is currently an advisory editor of the journal Cell Metabolism. His main research achievement has been the discovery of the AMP-activated protein kinase (AMPK) and the elucidation of its physiological function.  This system, which monitors the energy balance of every living cell, is also intimately involved in the regulation of whole body energy balance, and is a key player in obesity and Type 2 diabetes. The AMPK system appears to be responsible for the beneficial effects of exercise on the development of the latter conditions, is a target for the existing anti-diabetic drug metformin and the anti-inflammatory drug salicylate, and for the development of novel drugs.
Grahame Hardie also discovered that the tumour suppressor LKB1 acted upstream of AMPK, providing a link between AMPK and cancer. This has led to the development of clinical trials of the efficacy of metformin treatment in cancer.